Formulary
Meningococcal group B vaccine (rDNA, component, adsorbed): Indications, Dosing, Side Effects and Interactions
B vaccine (rDNA, component, adsorbed) Meningococcal group B vaccine is a non-live vaccine that contains adsorbed recombinant Neisseria meningitidis serogroup...
MedNext Academy | 5 min read
Meningococcal group B vaccine (rDNA, component, adsorbed): Indications, Dosing, Side Effects and Interactions
B vaccine (rDNA, component, adsorbed) Meningococcal group B vaccine is a non-live vaccine that contains adsorbed recombinant Neisseria meningitidis serogroup...
Drug action
B vaccine (rDNA, component, adsorbed) Meningococcal group B vaccine is a non-live vaccine that contains adsorbed recombinant Neisseria meningitidis serogroup B proteins.
Indications and dose
**Primary immunisation againstNeisseria meningitidisgroup B**
- **Child** (By Intramuscular Injection): Primary immunisation against Neisseria meningitidis group B 2-3 months 0.5 mL for 2 doses, first dose to be given at 8 weeks of age and second dose to be given at 12 weeks of age.
**Immunisation againstNeisseria meningitidisgroup B [booster dose]**
- **Child** (By Intramuscular Injection): Immunisation against Neisseria meningitidis group B [booster dose] 1 year 0.5 mL for 1 dose.
**Immunisation againstNeisseria meningitidisgroup B [patients with unknown or incomplete immunisation status presenting before 1 year of age]**
- **Child** (By Intramuscular Injection): Immunisation against Neisseria meningitidis group B [patients with unknown or incomplete immunisation status presenting before 1 year of age] 3-11 months 0.5 mL for 3 doses, first and second doses separated by an interval of at least 4 weeks, then third dose to be given between 1 and 2 years of age and at least 4 weeks after the second dose.
**Immunisation againstNeisseria meningitidisgroup B [patients with unknown or incomplete immunisation status presenting after 1 year of age]**
- **Child** (By Intramuscular Injection): Immunisation against Neisseria meningitidis group B [patients with unknown or incomplete immunisation status presenting after 1 year of age] 12-23 months 0.5 mL for 2 doses, doses to be separated by an interval of at least 4 weeks.
**Immunisation againstNeisseria meningitidis, primary immunisation**
- **Child** (By Intramuscular Injection): Immunisation against Neisseria meningitidis , primary immunisation 10-17 years 0.5 mL for 2 doses, separated by an interval of 6 months, alternatively 0.5 mL for 2 doses, separated by an interval of at least 1 month, followed by 0.5 mL as a third dose, given at least 4 months after the second dose, injected preferably into deltoid region, a booster dose should be considered for individuals at continued risk-consult product literature.
- **Adult** (By Intramuscular Injection): 0.5 mL for 2 doses, separated by an interval of 6 months, alternatively 0.5 mL for 2 doses, separated by an interval of at least 1 month, followed by 0.5 mL as a third dose, given at least 4 months after the second dose, injected preferably into deltoid region, a booster dose should be considered for individuals at continued risk-consult product literature.
**Primary immunisation against Neisseria meningitidis group B for Bexsero**
- **Child 2-3 months** (By intramuscular injection): 0.5 mL for 2 doses, first dose to be given at 8 weeks of age and second dose to be given at 12 weeks of age.
**Immunisation against Neisseria meningitidis group B [booster dose] for Bexsero**
- **Child 1 year** (By intramuscular injection): 0.5 mL for 1 dose.
**Immunisation against Neisseria meningitidis group B [patients with unknown or incomplete immunisation status presenting before 1 year of age] for Bexsero**
- **Child 3-11 months** (By intramuscular injection): 0.5 mL for 3 doses, first and second doses separated by an interval of at least 4 weeks, then third dose to be given between 1 and 2 years of age and at least 4 weeks after the second dose.
**Immunisation against Neisseria meningitidis group B [patients with unknown or incomplete immunisation status presenting after 1 year of age] for Bexsero**
- **Child 12-23 months** (By intramuscular injection): 0.5 mL for 2 doses, doses to be separated by an interval of at least 4 weeks.
**Immunisation against Neisseria meningitidis, primary immunisation for Trumenba**
- **Child 10-17 years** (By intramuscular injection): 0.5 mL for 2 doses, separated by an interval of 6 months, alternatively 0.5 mL for 2 doses, separated by an interval of at least 1 month, followed by 0.5 mL as a third dose, given at least 4 months after the second dose, injected preferably into deltoid region, a booster dose should be considered for individuals at continued risk-consult product literature.
Cautions
For all vaccines, general Acute illness; minor illnesses Cautions, further information Illness UKHSA advises vaccination may be postponed if the individual is suffering from an acute illness; however, it is not necessary to postpone immunisation in patients with minor illnesses without fever or systemic upset. Predisposition to neurological problems UKHSA advises: when there is a personal or family history of febrile convulsions, there is an increased risk of these occurring during fever from any cause including immunisation, but this is not a contra-indication to immunisation. In children who have had a seizure associated with fever without neurological deterioration, immunisation is recommended ; advice on the management of fever should be given before immunisation. When a child has had a convulsion not associated with fever, and the neurological condition is not deteriorating, immunisation is recommended ; children with stable neurological disorders (e.g. spina bifida, congenital brain abnormality, and peri-natal hypoxic-ischaemic encephalopathy) should be immunised according to the recommended schedule; when there is a still evolving neurological problem , including poorly controlled epilepsy, immunisation should be deferred and the child referred to a specialist. Immunisation is recommended if a cause for the neurological disorder is identified. If a cause is not identified, immunisation should be deferred until the condition is stable. Impaired immune response and drugs affecting immune response Immune response to vaccines may be reduced in immunosuppressed patients, UKHSA advises consider seeking specialist advice.
Side effects
For all vaccines, general Common or very common Abdominal pain; appetite decreased; arthralgia; diarrhoea; dizziness; fatigue; fever; headache; lymphadenopathy; malaise; myalgia; nausea; skin reactions; vomiting Uncommon Hypersensitivity Side-effects For meningococcal group B vaccine (rDNA, component, adsorbed) Common or very common Crying abnormal (in children); drowsiness (in children); eating disorder (in children); irritability (in children) Uncommon Seizures (in children); vascular disorders (in children) Frequency not known Extensive swelling of vaccinated limb; hypotonic-hyporesponsiveness episode (in children); meningism
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Meningococcal group B vaccine (rDNA, component, adsorbed) in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

